• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伴有中枢神经系统受累的厄尔德海姆-切斯特病:一种罕见组织细胞增多症中的复杂组织病理学诊断及神经外科挑战

Erdheim-Chester with central nervous system involvement: Complex histopathological diagnosis and neurosurgical challenges in a rare histiocytic disorder.

作者信息

Toache Kevin S, Puentes-Rosero Santiago, Zenteno-Zenteno Massiel, Castellanos-Pallares Luis Guillermo, Rodriguez-Florido Marco A, Gonzalez-Zavala Pedro Adrian

机构信息

Department of Neurosurgery, National Medical Center, Mexico City, Mexico.

Department of Neuropathology, National Medical Center, Mexico City, Mexico.

出版信息

Surg Neurol Int. 2025 May 23;16:202. doi: 10.25259/SNI_199_2025. eCollection 2025.

DOI:10.25259/SNI_199_2025
PMID:40469323
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12134830/
Abstract

BACKGROUND

Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis classified as a neoplastic hematopoietic disorder. It typically affects adults aged 40-56 years, with a male predominance (2.3-3:1). ECD presents with a wide clinical spectrum, ranging from asymptomatic bone lesions (90% of cases) to severe multisystem involvement, including cardiovascular, pulmonary, and central nervous systems (CNSs). CNS involvement occurs in approximately 50% of cases and is associated with increased morbidity and mortality. The BRAF V600E mutation is found in a significant subset of patients and plays a critical role in diagnosis and targeted therapy.

CASE DESCRIPTION

We present the case of a 39-year-old male with central hypothyroidism, progressive visual impairment, and headaches. Magnetic resonance imaging revealed two extra-axial supratentorial lesions. Surgical resection was performed using a "one-and-a-half " frontotemporal craniotomy, providing optimal multi-angled access. Histopathological examination confirmed ECD with a BRAF V600E mutation. The patient had an uneventful postoperative recovery.

CONCLUSION

This case highlights the strategic utility of the "one-and-a-half " frontotemporal craniotomy in the resection of complex supratentorial lesions. It also underscores the critical importance of molecular diagnostics, particularly the identification of the BRAF V600E mutation, in guiding treatment decisions in ECD.

摘要

背景

厄尔德海姆-切斯特病(ECD)是一种罕见的非朗格汉斯细胞组织细胞增多症,归类为肿瘤性造血系统疾病。它通常影响40至56岁的成年人,男性居多(2.3 - 3:1)。ECD临床表现多样,从无症状骨病变(90%的病例)到严重的多系统受累,包括心血管、肺和中枢神经系统(CNS)。约50%的病例会出现CNS受累,且与发病率和死亡率增加相关。BRAF V600E突变在相当一部分患者中被发现,在诊断和靶向治疗中起关键作用。

病例描述

我们报告一例39岁男性患者,有中枢性甲状腺功能减退、进行性视力损害和头痛症状。磁共振成像显示两个幕上脑外病变。采用“一点半”额颞开颅术进行手术切除,可提供最佳多角度入路。组织病理学检查确诊为ECD伴BRAF V600E突变。患者术后恢复顺利。

结论

该病例突出了“一点半”额颞开颅术在切除复杂幕上病变中的策略性效用。它还强调了分子诊断,特别是BRAF V600E突变的鉴定,在指导ECD治疗决策中的至关重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2587/12134830/c6da68f3057f/SNI-16-202-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2587/12134830/63eac96a1aa5/SNI-16-202-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2587/12134830/895b424a3c8e/SNI-16-202-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2587/12134830/c58aa3e29eac/SNI-16-202-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2587/12134830/32717a11face/SNI-16-202-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2587/12134830/c6da68f3057f/SNI-16-202-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2587/12134830/63eac96a1aa5/SNI-16-202-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2587/12134830/895b424a3c8e/SNI-16-202-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2587/12134830/c58aa3e29eac/SNI-16-202-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2587/12134830/32717a11face/SNI-16-202-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2587/12134830/c6da68f3057f/SNI-16-202-g005.jpg

相似文献

1
Erdheim-Chester with central nervous system involvement: Complex histopathological diagnosis and neurosurgical challenges in a rare histiocytic disorder.伴有中枢神经系统受累的厄尔德海姆-切斯特病:一种罕见组织细胞增多症中的复杂组织病理学诊断及神经外科挑战
Surg Neurol Int. 2025 May 23;16:202. doi: 10.25259/SNI_199_2025. eCollection 2025.
2
BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.中枢神经系统(CNS-JXG)幼年黄色肉芽肿家族性肿瘤中的 BRAF V600E 突变:包括小儿神经鞘黏液瘤病在内的修订诊断算法。
Acta Neuropathol Commun. 2019 Nov 4;7(1):168. doi: 10.1186/s40478-019-0811-6.
3
Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report.达布拉非尼联合类固醇治疗广泛中枢神经系统累及的 Erdheim-Chester 病:一例报告。
Per Med. 2024;21(2):71-78. doi: 10.2217/pme-2023-0137. Epub 2024 Jan 26.
4
Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis.在用克拉屈滨成功治疗朗格汉斯细胞组织细胞增多症后发生的伴有眼眶和中枢神经系统受累的厄尔海姆-切斯特病。
Vojnosanit Pregl. 2016 Jan;73(1):83-7. doi: 10.2298/vsp140915037p.
5
Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.中国成人Erdheim-Chester病的临床病理特征及BRAF V600E突变评估
Ann Hematol. 2016 Apr;95(5):745-50. doi: 10.1007/s00277-016-2606-1. Epub 2016 Feb 9.
6
Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.达拉非尼治疗厄尔德海姆-切斯特病(ECD)的显著疗效:一名患有多发性颅内大ECD病变的儿科患者,这些病变被难治性朗格汉斯细胞组织细胞增多症掩盖。
J Neurosurg Pediatr. 2019 Jan 1;23(1):48-53. doi: 10.3171/2018.6.PEDS17728. Epub 2018 Sep 28.
7
Erdheim-Chester disease with bilateral orbital masses and multi-systemic symptoms: two case reports.双侧眼眶肿块伴多系统症状的 Erdheim-Chester 病:两例报告。
World J Surg Oncol. 2023 Jul 31;21(1):233. doi: 10.1186/s12957-023-03123-5.
8
The clinical spectrum and prognostic factors of Erdheim-Chester disease and mixed Langerhans cell histiocytosis and Erdheim-Chester disease.厄尔德海姆-切斯特病以及混合性朗格汉斯细胞组织细胞增多症与厄尔德海姆-切斯特病的临床谱及预后因素
Ann Hematol. 2023 Dec;102(12):3335-3343. doi: 10.1007/s00277-023-05501-1. Epub 2023 Nov 3.
9
Coexistence of intracranial Langerhans cell histiocytosis and Erdheim-Chester disease in a pediatric patient: a case report.一名儿科患者颅内朗格汉斯细胞组织细胞增多症与 Erdheim-Chester 病并存:病例报告
Childs Nerv Syst. 2016 May;32(5):893-6. doi: 10.1007/s00381-015-2929-6. Epub 2015 Oct 14.
10
Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.成人朗格汉斯细胞组织细胞增多症和 Erdheim-Chester 病的造血起源
Blood. 2017 Jul 13;130(2):167-175. doi: 10.1182/blood-2016-12-757823. Epub 2017 May 16.

本文引用的文献

1
Erdheim-Chester Disease with Isolated CNS Involvement: A Systematic Review of the Literature.以中枢神经系统单独受累为表现的厄尔海姆-切斯特病:文献系统综述
Neurol Int. 2022 Sep 5;14(3):716-726. doi: 10.3390/neurolint14030060.
2
Neurological manifestations of Erdheim-Chester Disease.脑白质营养不良的神经表现。
Ann Clin Transl Neurol. 2020 Apr;7(4):497-506. doi: 10.1002/acn3.51014. Epub 2020 Mar 29.
3
The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. Erdheim-Chester 病的组织病理学:对分子特征明确队列的全面综述。
Mod Pathol. 2018 Apr;31(4):581-597. doi: 10.1038/modpathol.2017.160. Epub 2017 Dec 1.
4
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.维莫非尼治疗 BRAF V600 突变型 Erdheim-Chester 病和朗格汉斯细胞组织细胞增生症:来自组织学独立、开放标签 VE-BASKET 研究的数据分析。
JAMA Oncol. 2018 Mar 1;4(3):384-388. doi: 10.1001/jamaoncol.2017.5029.
5
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.巨噬细胞-树突状细胞谱系组织细胞增多症和肿瘤的修订分类
Blood. 2016 Jun 2;127(22):2672-81. doi: 10.1182/blood-2016-01-690636. Epub 2016 Mar 10.
6
Erdheim-Chester disease: a systematic review.Erdheim-切斯特病:一项系统综述。
Crit Rev Oncol Hematol. 2015 Jul;95(1):1-11. doi: 10.1016/j.critrevonc.2015.02.004. Epub 2015 Feb 17.
7
Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.BRAF(V600E) 突变型 Erdheim-Chester 病患者应用 vemurafenib 的可重现和持续疗效。
J Clin Oncol. 2015 Feb 10;33(5):411-8. doi: 10.1200/JCO.2014.57.1950. Epub 2014 Nov 24.
8
Erdheim-Chester Disease: a comprehensive review of the literature.厄德海姆-切斯特病:文献综述。
Orphanet J Rare Dis. 2013 Sep 8;8:137. doi: 10.1186/1750-1172-8-137.
9
Erdheim-Chester disease.厄德海姆-切斯特病。
Curr Opin Rheumatol. 2012 Jan;24(1):53-9. doi: 10.1097/BOR.0b013e32834d861d.
10
Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients.特发性骨纤维化中细胞因子和趋化因子网络的全身性紊乱:37 例患者的单中心系列研究。
Blood. 2011 Mar 10;117(10):2783-90. doi: 10.1182/blood-2010-10-313510. Epub 2011 Jan 4.